Krystal Biotech Has Dosed The First Patient In The Company's Phase 1 CORAL-1/US Study Of KB407 For Cystic Fibrosis; The Primary Endpoint Will Be The Safety, Tolerability Of Nebulized KB407, With Data Anticipated In 2024
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has initiated its Phase 1 CORAL-1/US study of KB407 for Cystic Fibrosis, with the first patient being dosed. The primary focus of the study will be the safety and tolerability of nebulized KB407, with data expected in 2024.

July 03, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Krystal Biotech has started its Phase 1 study of KB407 for Cystic Fibrosis. The study's primary endpoint is the safety and tolerability of the drug, with results expected in 2024.
The initiation of a Phase 1 study is a significant step for Krystal Biotech, indicating progress in their drug development pipeline. However, as the results are not expected until 2024, the immediate impact on the stock price is likely to be neutral. The long-term impact will depend on the study results.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100